Anti-CD22 Polyclonal Antibody (HB011014)

Name: Anti-CD22 Polyclonal Antibody
Brand: abinScience
SKU: HB011014
Price: 168 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD):

Spec:

50ug
100ug

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.

HB011014

Description

Anti-CD22 Polyclonal Antibody (HB011014) is a rabbit polyclonal antibody detecting CD22 in ELISA, IHC, WB. Suitable for Human, Pan paniscus, Pan troglodytes, and Pongo pygmaeus.

Highlights

●Affinity Purified — Minimal background and high purity for reliable results.
●Multi-Application — Validated across multiple applications.
●Multi-Species — Cross-reactive for translational research.

Species reactivity

Human, Gorilla gorilla gorilla, Pan paniscus, Pan troglodytes, Pongo pygmaeus

Applications

ELISA, IHC, WB

Host species

Rabbit

Isotype

IgG

Clonality

Polyclonal

Immunogen

E. coli - derived recombinant Human CD22 (Trp176-Ala330).

Target

Sialic acid-binding Ig-like lectin 2, Siglec-2, CD22, T-cell surface antigen Leu-14, BL-CAM, SIGLEC2, B-lymphocyte cell adhesion molecule, B-cell receptor CD22

Purification

Purified by antigen affinity column.

Accession

P20273

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Product Usage Information

Application	Dilution
ELISA	1:5000-1:20000
IHC	1:50-1:500
WB	1:500-1:2000

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Background

B-cell receptor CD22 is a ~95 kDa protein. Most highly expressed siglec (sialic acid-binding immunoglobulin-like lectin) on B-cells that plays a role in various aspects of B-cell biology including differentiation, antigen presentation, and trafficking to bone marrow. Binds to alpha 2,6-linked sialic acid residues of surface molecules such as CD22 itself, CD45 and IgM in a cis configuration. Can also bind to ligands on other cells as an adhesion molecule in a trans configuration. Acts as an inhibitory coreceptor on the surface of B-cells and inhibits B-cell receptor induced signaling, characterized by inhibition of the calcium mobilization and cellular activation. Mechanistically, the immunoreceptor tyrosine-based inhibitory motif domain is phosphorylated by the Src kinase LYN, which in turn leads to the recruitment of the protein tyrosine phosphatase 1/PTPN6, leading to the negative regulation of BCR signaling. CD22 is the therapeutic target of inotuzumab ozogamicin (Besponsa).

1. Meyer, SJ. et al. (2021) Journal of immunology (Baltimore, Md. : 1950) 207, 1018-1032. PMID: 34330755

2. Law, CL. et al. (1996) The Journal of experimental medicine 183, 547-60. PMID: 8627166

3. Ramya, TN. et al. (2010) Molecular & cellular proteomics : MCP 9, 1339-51. PMID: 20172905

4. Séïté, JF. et al. (2010) Blood 116, 1698-704. PMID: 20516366

Note

For research use only.

Images